Kauppila A, Martikainen H, Puistola U, Reinilä M, Rönnberg L
Department of Obstetrics and Gynecology, University of Oulu, Finland.
Fertil Steril. 1988 Mar;49(3):437-41.
Thirty-two patients with ovarian hyperstimulation were randomized to receive bromocriptine or placebo from cycle day 5 onward. Bromocriptine decreased serum and follicular fluid prolactin (PRL), accelerated ovarian follicle growth, increased serum and follicular fluid estradiol, lowered luteal phase progesterone, and shortened the luteal phase length of the cycle. The maximal luteal phase estradiol and progesterone concentrations correlated with each other in the placebo group, but not in the bromocriptine group. These findings indicate that hypoprolactinemia interferes with ovarian function. The unchanged concentrations of gonadotropic hormones and pattern of luteinizing hormone pulsation during bromocriptine suggest direct ovarian effects of hypoprolactinemia. Because PRL suppression enhanced follicular responses and inhibited corpus luteum formation and function, the follicular and corpus luteum actions of PRL may be different.
32例卵巢过度刺激患者从周期第5天起被随机分为接受溴隐亭或安慰剂治疗组。溴隐亭可降低血清和卵泡液催乳素（PRL）水平，加速卵巢卵泡生长，增加血清和卵泡液雌二醇水平，降低黄体期孕酮水平，并缩短周期的黄体期长度。安慰剂组黄体期雌二醇和孕酮的最大浓度相互相关，而溴隐亭组则不然。这些发现表明低催乳素血症会干扰卵巢功能。溴隐亭治疗期间促性腺激素浓度未改变以及促黄体生成素脉冲模式表明低催乳素血症对卵巢有直接影响。由于PRL抑制增强了卵泡反应并抑制了黄体形成和功能，PRL对卵泡和黄体的作用可能不同。
